Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MUQDAD ZURIQAT

NPI
1417962887
CMS profile
154410
Location
SHERMAN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$2,970.50

164 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,936.50 163
Education $34.00 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 164 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MUQDAD ZURIQAT

NPI 1417962887 · CMS profile ID 154410

SHERMAN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 164 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417962887?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MUQDAD ZURIQAT, NPI 1417962887, CMS profile ID 154410. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 164 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417962887?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MUQDAD ZURIQAT, NPI 1417962887, CMS profile ID 154410. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 164 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417962887?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MUQDAD ZURIQAT, NPI 1417962887, CMS profile ID 154410, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 164 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1417962887?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

164 matching records · $2,970.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 164 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 164.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Viatris Specialty LLC $16.9605/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238508145 CMS
AstraZeneca Pharmaceuticals LP $16.0004/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214794134 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.7604/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223817838 CMS
GENZYME CORPORATION $17.1304/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233382117 CMS
Amgen Inc. $18.3204/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228659825 CMS
AstraZeneca Pharmaceuticals LP $17.4104/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214796130 CMS
GENZYME CORPORATION $34.4204/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233382111 CMS
GENZYME CORPORATION $15.7204/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233382119 CMS
Baxter Healthcare $16.2504/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181705227 CMS
Baxter Healthcare $16.6804/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181705229 CMS
GlaxoSmithKline, LLC. $19.7204/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191105060 CMS
Actelion Pharmaceuticals US, Inc. $34.7704/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174308041 CMS
Viatris Specialty LLC $18.9004/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238508163 CMS
Grifols USA, LLC $18.2904/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249570088 CMS
Amgen Inc. $19.0303/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228659815 CMS
Baxter Healthcare $22.3803/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181705225 CMS
GlaxoSmithKline, LLC. $9.0603/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190418955 CMS
Bayer Healthcare Pharmaceuticals Inc. $23.0103/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225924504 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.7203/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223806352 CMS
Insmed, Inc. $2.0603/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186286592 CMS
Actelion Pharmaceuticals US, Inc. $26.6303/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174308033 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.5503/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223806175 CMS
GlaxoSmithKline, LLC. $11.6303/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190689916 CMS
Insmed, Inc. $12.5503/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186259881 CMS
GlaxoSmithKline, LLC. $20.4203/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191478620 CMS
Amgen Inc. $19.4803/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228659823 CMS
Viatris Specialty LLC $22.7303/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238508091 CMS
GENZYME CORPORATION $15.7002/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233382085 CMS
Grifols USA, LLC $18.9402/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249570086 CMS
GlaxoSmithKline, LLC. $15.9802/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190708569 CMS
Baxter Healthcare $5.5302/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181705223 CMS
GlaxoSmithKline, LLC. $17.9502/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190648970 CMS
United Therapeutics Corporation $32.7202/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242525504 CMS
Viatris Specialty LLC $7.9902/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238508083 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.2902/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222975105 CMS
AstraZeneca Pharmaceuticals LP $14.3702/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214775082 CMS
AstraZeneca Pharmaceuticals LP $22.1802/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1215332359 CMS
GENZYME CORPORATION $13.0002/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233382081 CMS
GlaxoSmithKline, LLC. $17.2802/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191596876 CMS
Merck Sharp & Dohme LLC $26.7202/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238085053 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.2402/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222975107 CMS
AstraZeneca Pharmaceuticals LP $100.8502/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214771898 CMS
GlaxoSmithKline, LLC. $15.1102/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191557966 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.1102/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223808090 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.8301/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222975115 CMS
Merck Sharp & Dohme LLC $29.7801/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238270604 CMS
GlaxoSmithKline, LLC. $15.3401/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191187132 CMS
Takeda Pharmaceuticals U.S.A., Inc. $0.8101/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223796370 CMS
Takeda Pharmaceuticals U.S.A., Inc. $9.3901/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223805084 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.7901/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225924496 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,365.13 106
PY2020 $1,478.76 97
PY2021 $1,841.37 118
PY2022 $1,966.90 117
PY2023 $1,874.40 100
PY2024 $2,765.94 155
PY2025 $2,970.50 164

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $140,117.51 25
PY2024 Principal investigator $236,094.31 36
PY2023 Principal investigator $213,012.99 43
PY2022 Principal investigator $221,270.32 57
PY2021 Principal investigator $178,767.79 46
PY2020 Principal investigator $233,851.36 43
PY2019 Recipient $415.38 1
PY2019 Principal investigator $143,002.98 31

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Verona Pharma, Inc. $11,867.11 12/19/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891381
Principal investigator 1 Genentech, Inc. $372.00 11/13/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211654346
Principal investigator 1 Genentech, Inc. $238.00 11/13/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211654350
Principal investigator 1 Genentech, Inc. $2,000.00 11/13/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211654354
Principal investigator 1 Genentech, Inc. $558.00 11/13/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211654358
Principal investigator 1 Genentech, Inc. $504.00 11/13/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211654361
Principal investigator 1 Genentech, Inc. $434.00 11/13/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211654371
Principal investigator 1 Genentech, Inc. $1,238.00 11/13/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211654375
Principal investigator 1 Genentech, Inc. $383.00 11/05/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211654367
Principal investigator 1 Genentech, Inc. $383.50 11/05/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211654379
Principal investigator 1 Verona Pharma, Inc. $10,000.00 08/20/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891327
Principal investigator 1 Verona Pharma, Inc. $1,800.00 08/20/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891329
Principal investigator 1 Genentech, Inc. $23,750.00 07/22/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211654336
Principal investigator 1 Genentech, Inc. $1,794.00 07/16/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211654341
Principal investigator 1 SANOFI US SERVICES INC. $6,300.00 06/09/2025 Non-covered Recipient Entity
Sherman Clinical Research
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226108369
Principal investigator 1 Genentech, Inc. $154.00 05/28/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211654316
Principal investigator 1 Genentech, Inc. $200.00 05/28/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211654319
Principal investigator 1 Genentech, Inc. $1,866.90 05/28/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211654323
Principal investigator 1 Genentech, Inc. $128.00 05/28/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211654327
Principal investigator 1 Genentech, Inc. $8,344.00 05/07/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211654334
Principal investigator 1 Genentech, Inc. $30,589.00 05/06/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211654330
Principal investigator 1 Genentech, Inc. $34,844.00 02/06/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211654310
Principal investigator 1 GlaxoSmithKline, LLC. $1,320.00 02/05/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1192110883
Principal investigator 1 Genentech, Inc. $476.00 01/09/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211654307
Principal investigator 1 Genentech, Inc. $574.00 01/09/2025 Non-covered Recipient Entity
SHERMAN CLINICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211654313